DUBLIN--(BUSINESS WIRE)--The "Protein Kinase Inhibitors in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.
Kinase-targeted cancer therapies became really big with imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with chronic myelogenous leukemia. With the human genome encoding 538 protein kinases and many of these kinases being associated with human cancer initiation and progression, this field carries a lot of promise for more treatment successes in the future.
Protein Kinase Inhibitors in Oncology: Analytical Tool is the most up to date and comprehensive commercial pipeline review and competitive assessment available on this hot and fast moving area in oncology. This unique product is truly the only one of its kind and is designed to give you a competitive edge in your PKI drug intelligence.
Your Protein Kinase Inhibitors in Oncology: Analytical Tool is based on two decades of proven methodology in serving clients with interest in:
- Target Scouting
- Early & Late Stage Pipeline Analysis
- Biomarker/Companion Diagnostic Analysis
- Deal & Alliance Analysis
- Combination Therapy Analysis
- Clinical Trial Results Analysis
- Indication Selection & Expansion Analysis
- First-in-Class Analysis
- Drug Repositioning
-
Pipeline Analysis by Targeted Pathways
Your Protein Kinase Inhibitors in Oncology: Analytical Tool covers more than 509 companies plus partners who are today developing 1668 PKI drugs where of 941 are in active developmental in cancer across 322 different targets.
For more information about this report visit https://www.researchandmarkets.com/research/3tjr6j/protein_kinase?w=4
